Clinical Study of IBI362 in Healthy Chinese Male Subjects

Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Study ID
NCT04773977
Phase
PHASE1
Status
Completed

Conditions

  • Overweight/Obesity

Eligibility Criteria

Sex
MALE
Age
20 Years - 45 Years
Healthy Volunteers
Accepted

Interventions

  • IBI362 liquid formulation — DRUG
    Administered by subcutaneous injection
  • IBI362 lyophilized powder — DRUG
    Administered by subcutaneous injection

Study Details

This is a study to evaluate the pharmacokinetic characteristics and safety of IBI362 lyophilized powder and IBI362 liquid formulation in healthy Chinese male subjects.

Key Dates

Start date
Mar 3, 2021
Status verified
Mar 2021
Primary completion
Mar 9, 2021
Completion
Jun 17, 2021

Study Design

Enrollment
24 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: IBI362 liquid formulation
    Participants received single subcutaneous injection of IBI362 liquid formulation
  • Experimental: IBI362 lyophilized powder
    Participants received single subcutaneous injection of IBI362 lyophilized powder

Primary Outcome Measure

Evaluate the PK parameters of IBI362 in healthy Chinese male subjects [ Time Frame: From the first dose of study drug until 8 weeks ]

Related Studies